Investigation of the effect of hepatic metabolism on off-target cardiotoxicity in a multi-organ human-on-a-chip system

被引:121
作者
Oleaga, Carlota [1 ]
Riu, Anne [2 ]
Rothemund, Sandra [1 ]
Lavado, Andrea [1 ]
McAleer, Christopher W. [1 ,4 ]
Long, Christopher J. [1 ,4 ]
Persaud, Keisha [1 ]
Narasimhan, Narasimhan Sriram [4 ]
My Tran [4 ]
Roles, Jeffry [1 ]
Carmona-Moran, Carlos A. [1 ]
Sasserath, Trevor [4 ]
Elbrecht, Daniel H. [1 ,4 ]
Kumanchik, Lee [1 ]
Bridges, L. Richard [4 ]
Martin, Candace [1 ]
Schnepper, Mark T. [1 ]
Ekman, Gail [1 ]
Jackson, Max [1 ]
Wang, Ying I. [1 ,5 ]
Note, Reine [2 ]
Langer, Jessica [3 ]
Teissier, Silvia [2 ]
Hickman, James J. [1 ]
机构
[1] Univ Cent Florida, NanoSci Technol Ctr, 12424 Res Pkwy,Suite 400, Orlando, FL 32826 USA
[2] LOreal Res & Innovat Div, Aulnay Sous Bois, France
[3] LOreal Res & Innovat Div, Clark, NJ USA
[4] Hesperos Inc, 3259 Progress Dr,Room 158, Orlando, FL 32826 USA
[5] Cornell Univ, Nancy E & Peter C Meinig Sch Biomed Engn, Ithaca, NY 14853 USA
关键词
Human-on-a-chip; Functional readouts; Cardiotoxicity; Non-invasive; Metabolism; CELL-DERIVED CARDIOMYOCYTES; HIGH-DOSE CYCLOPHOSPHAMIDE; DRUG-DRUG INTERACTION; IN-VITRO SYSTEM; HUMAN PLASMA; MICROPHYSIOLOGICAL SYSTEM; PHARMACEUTICAL RESEARCH; MICROFLUIDIC CELL; HUMAN HEPATOCYTES; ANTICANCER DRUGS;
D O I
10.1016/j.biomaterials.2018.07.062
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Regulation of cosmetic testing and poor predictivity of preclinical drug studies has spurred efforts to develop new methods for systemic toxicity. Current in vitro assays do not fully represent physiology, often lacking xenobiotic metabolism. Functional human multi-organ systems containing iPSC derived cardiomyocytes and primary hepatocytes were maintained under flow using a low-volume pumpless system in a serum-free medium. The functional readouts for contractile force and electrical conductivity enabled the non-invasive study of cardiac function. The presence of the hepatocytes in the system induced cardiotoxic effects from cyclophosphamide and reduced them for terfenadine due to drug metabolism, as expected from each compound's pharmacology. A computational fluid dynamics simulation enabled the prediction of terfenadine-fexofenadine pharmacokinetics, which was validated by HPLC-MS. This in vitro platform recapitulates primary aspects of the in vivo crosstalk between heart and liver and enables pharmacological studies, involving both organs in a single in vitro platform. The system enables non-invasive readouts of cardiotoxicity of drugs and their metabolites. Hepatotoxicity can also be evaluated by biomarker analysis and change in metabolic function. Integration of metabolic function in toxicology models can improve adverse effects prediction in preclinical studies and this system could also be used for chronic studies as well.
引用
收藏
页码:176 / 190
页数:15
相关论文
共 101 条
[1]   Pumpless microfluidic platform for drug testing on human skin equivalents [J].
Abaci, Hasan Erbil ;
Gledhill, Karl ;
Guo, Zongyou ;
Christiano, Angela M. ;
Shuler, Michael L. .
LAB ON A CHIP, 2015, 15 (03) :882-888
[2]   Microfluidic heart on a chip for higher throughput pharmacological studies [J].
Agarwal, Ashutosh ;
Goss, Josue Adrian ;
Cho, Alexander ;
McCain, Megan Laura ;
Parker, Kevin Kit .
LAB ON A CHIP, 2013, 13 (18) :3599-3608
[3]  
Anderson LW, 1996, CLIN CANCER RES, V2, P1481
[4]  
[Anonymous], 2014, J VIS EXP, DOI DOI 10.1007/s10544-007-9116-9
[5]   Cardiotoxicity following cyclophosphamide therapy: a case report [J].
Atalay F. ;
Gulmez O. ;
Ozsancak Ugurlu A. .
Journal of Medical Case Reports, 8 (1)
[6]   CYCLOPHOSPHAMIDE PHARMACOKINETICS - CORRELATION WITH CARDIAC TOXICITY AND TUMOR RESPONSE [J].
AYASH, LJ ;
WRIGHT, JE ;
TRETYAKOV, O ;
GONIN, R ;
ELIAS, A ;
WHEELER, C ;
EDER, JP ;
ROSOWSKY, A ;
ANTMAN, K ;
FREI, E .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (06) :995-1000
[7]   Role of Biotransformation in Drug-Induced Toxicity: Influence of Intra-and Inter-Species Differences in Drug Metabolism [J].
Baillie, Thomas A. ;
Rettie, Allan E. .
DRUG METABOLISM AND PHARMACOKINETICS, 2011, 26 (01) :15-29
[8]   The heart-liver metabolic axis: defective communication exacerbates disease [J].
Baskin, Kedryn K. ;
Bookout, Angie L. ;
Olson, Eric N. .
EMBO MOLECULAR MEDICINE, 2014, 6 (04) :436-438
[9]   The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective [J].
Bjornsson, TD ;
Callaghan, JT ;
Einolf, HJ ;
Fischer, V ;
Gan, L ;
Grimm, S ;
Kao, J ;
King, SP ;
Miwa, G ;
Ni, L ;
Kumar, G ;
McLeod, J ;
Obach, RS ;
Roberts, S ;
Roe, A ;
Shah, A ;
Snikeris, F ;
Sullivan, JT ;
Tweedie, D ;
Vega, JM ;
Walsh, J ;
Wrighton, SA .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (07) :815-832
[10]  
Bolleyn J, 2015, METHODS MOL BIOL, V1250, P317, DOI 10.1007/978-1-4939-2074-7_24